GlycoT has executed a license agreement with Innovent Biologics (HK) Ltd (“Innovent”) in its key ADC Technology. Under this license, Innovent will acquire non-exclusive worldwide rights to use GlycoT’s site-specific antibody bioconjugation technology to develop, manufacture and commercialize antibody-drug conjugate (ADC) products. As part of the collaboration, GlycoT will provide technical support during the R&D stage, and Innovent will share certain agreed preclinical data with GlycoT. This deal includes undisclosed upfront and milestone payments. GlycoT’s platform uses a single enzyme (an endoglycosidase) for simultaneous antibody de-glycosylation and re-glycosylation with a functionalized disaccharide moiety in a one-pot manner, allowing a site-specific antibody conjugation with tags, drugs, ligands, or any other molecular entities. This technology provides a general and highly efficient platform for producing homogeneous site-specific ADCs.
“I am very pleased with the partnership.” said Dr. Lai-Xi Wang, Founder and President of GlycoT Therapeutics and a Distinguished University Professor of the University of Maryland, College Park. "Innovent has a strong track record of developing antibody-based therapeutics. We believe that this collaboration will promote the glycosite-specific conjugation technology for antibody bioconjugation and drive the development of more effective antibody-drug conjugates for treating human diseases.”
Dr. Kaijie He, Vice President of Cancer Biology and ADC research at Innovent, said: “We are glad to collaborate with GlycoT as Innovent is strengthening its presence in the ADC area. In addition to the ADC technologies Innovent currently uses, this collaboration will introduce a unique, advanced One-Pot Single-Enzyme technology, enabling Innovent to further build on its understanding of ADC research and ADC pipeline development.”
About GlycoT Therapeutics LLC
GlycoT Therapeutics aims to apply its innovative chemoenzymatic glycosylation technology for glycoengineering of therapeutic proteins such as monoclonal antibodies to improve their therapeutic efficacy. This includes novel enzymatic methods for making homogeneous antibody glycoforms with optimal biological activities and for producing site-specific antibody-drug conjugates. For more information, visit www.glycot.com.
About Innovent
Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that treat some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has 14 products in the market, 3 new drug applications under the NMPA review, 4 assets in Phase III or pivotal clinical trials and 15 more molecules in early clinical stage. Innovent partners with over 30 global healthcare leaders, including Eli Lilly, Roche, Sanofi, Adimab, Incyte and MD Anderson Cancer Center. Guided by the motto, "Start with Integrity, Succeed through Action," Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit www.innoventbio.com, or follow Innovent on Facebook and LinkedIn.
Statement: Innovent does not recommend the use of any unapproved drug (s)/indication (s).